A variety of mRNA isoforms of TACC2 have been reported, including a 3.8-kb isoform termed anti-zuai-1 gene (AZU-1), and 4.2-kb and 9.7-kb major isoforms29; the isoform AZU-1 was originally considered a tumor suppressor gene29 but recent studies reported increased expression of TACC2 in breast cancer patients with poor prognosis56 and in prostate cancer patients with poor survival rate57. This evidence concerns the gene AZU1 and breast carcinoma.